Rewiring Antitumor Immunity: Targeting CLDN18.2 with Conditional 4-1BB Activation.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41020763.
- Also identified by DOI 10.1158/1078-0432.CCR-25-2554 and PMC identifier 12666305.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Claudin 18.2 has emerged as a validated target in solid tumors, spurring next-generation therapies. Bispecific antibodies linking Claudin 18.2 to conditional 4-1BB activation offer a novel approach to enhance T-cell function. By confining costimulation to the tumor microenvironment, they aim to boost efficacy while limiting systemic toxicity. See related article by Ku et al., p. 4944.
Medical subject headings
- Claudins
- Tumor Necrosis Factor Receptor Superfamily, Member 9
- Neoplasms
- Antibodies, Bispecific